Temple University is actively seeking business partners and entrepreneurs to advance discoveries created by our researchers. Please search our technologies below to view available opportunities for partnership. Since Temple researchers are continuously developing new technology that may be unpublished, we encourage you to contact us if you have specific business needs. Our office will work with you to explore whether those needs align with any Temple research, technologies, or other collaboration opportunities.
| Technology | |
|---|---|
| Intravenous needle insertion device C2023-023 |
About
Intravenous (IV) catheters and needles are used for numerous procedures, yet the insertion of the catheters and needles can be difficult, painful, and anxiety provoking to both the healthcare provider and the patient. Methods that can improve the insertion of peripheral IV catheters would decrease the need for multiple sticks, less wasted IV catheters, and less wasted time by the clinician. Failure of the IV insertion with the first attempt may require several attempts before being successful. Worse yet, the healthcare provider may not even be able to successfully insert the IV catheter, requiring more invasive procedures to obtain the necessary IV catheter or needle access. In addition, safety is always a concern when using sharp medical instruments. When attempting to insert an IV catheter or needle, the healthcare provider often needs to stabilize the vein with their non-dominant hand, close to the insertion site. This increases the risk of an accidental needle stick into the hand. We have developed a device to solve this problem A device that improves the insertion of the IV catheter into the vein would significantly improve the success rate and ease of insertion of the IV. This would minimize the anxiety of the patient and healthcare provider, and decrease the pain and potential complications of unguided IV needle insertions. By using the guide, the healthcare provider also minimizes the possibility of an accidental injury to themselves, thus making the IV catheter or needle insertion safer. The current device accomplishes each of these needs with a simple design that stabilizes the vein and guides the needle into the vein. Trials with IV nurses using a prototype device have been universally beneficial to the nurses such that they desired to have them available. As noted, the device is a simple, yet elegant functional design that is inexpensive to manufacture. Estimated production cost is approximately $0.20 per unit, which would allow for packaging with most IV infusion and access kits, along with any needles used for blood draws. Proposed Use Guiding IV needles and catheters
Creator(s)
Eric Gokcen Patent Provisional patent filed Contact J. Todd Abrams, PhD Senior Director, New Ventures and Business Development Office of the Vice President for Research Technology Commercialization and Business Development techtran@temple.edu http://www.temple.edu/research Keywords Other (Medical Devices); Clinical Applications; Life Sciences |
| System and Method to Detect Mechanically Damaged
Energy Storage Cells Using Electrical Signals C2022-026 |
About
The present invention provides novel methods and systems to detect mechanical damages in energy storage systems, particularly lithium-ion batteries. These novel methods enable the safety evaluation of Li-ion batteries. The methods are based on applying inputs in the form of voltage or current to Li ion batteries and measuring current or voltage as the output. The inputs can be in sinusoidal form. The measurements will be used to detect damaged batteries from intact ones. The tests are nondestructive, and the batteries can be returned to service if they pass the evaluation. The first method proposed in this invention is to perform impedance spectra measurements on batteries after cooling/warming them to specific set temperatures to determine their safety status. The second method includes performing impedance spectra measurement on the batteries in situ, without any need for an environmental chamber. In this method, after recording the spectra, an advanced analysis is applied to the result to extract the time constants of the system, the time constants then will be used to make predictions about the safety of the battery. The benefit of using this system includes: • Non-invasive and non-destructive, so that the cells and modules can be returned to service if they pass the test. • Fast and efficient, as there is no need to take CT-scan or other expensive and slow methods to detect the damage. • The testing and analysis can be done while the system is in operational mode with no required downtime. • Portable: the system requires small equipment and can be moved easily. • Increase the safety of energy systems and the useful life of their energy storage devices as they can stay in service without fear of fire and other hazards due to undetected mechanical damages. Proposed Use Portable, reliable, and safe battery safety testing system
Creator(s)
Mohsen Derakhshan, Elham Sahraei, Damoon Soudbakhsh Patent Provisional Application Filed Contact J. Todd Abrams, PhD Senior Director, New Ventures and Business Development Office of the Vice President for Research Technology Commercialization and Business Development techtran@temple.edu http://www.temple.edu/research Keywords Electronics & Circuits; Energy Storage; Energy |
| A novel index for measuring subgingival microbiome dysbiosis as diagnostic aid in periodontitis C2022-020 |
About
A machine learning approach was used to analyze previously published periodontitis/health microbiome data sets (449 samples in total) to develop an intuitive, clinically relevant subgingival microbiome dysbiosis index as a summary statistic of microbiome sequencing data. The index can have important applications including identification of patients/sites at risk of periodontitis as well as active sites, assessment of microbial response to treatment, and, importantly, as a quantitative tool in microbiome modulation studies. We performed machine learning analysis of published periodontitis/health 16S microbiome data. The raw sequencing data, split into training and test sets, were quality filtered, taxonomically assigned to the species level, and centered log-ratio transformed. The training data set was subject to random forest analysis to identify discriminating species (DS) between periodontitis and health. DS lists, compiled by various “Gini” importance score cutoffs, were used to compute the SMDI for samples in the training and test data sets as the mean centered log-ratio abundance of periodontitis-associated species subtracted by that of health-associated ones. Diagnostic accuracy was assessed with receiver operating characteristic analysis. An SMDI based on 49 DS provided the highest accuracy with areas under the curve of 0.96 and 0.92 in the training and test data sets, respectively, and ranged from −6 (most normobiotic) to 5 (most dysbiotic) with a value around zero discriminating most of the periodontitis and healthy samples. The index was highly reproducible by hypervariable region. Applying the index to additional test data sets in which nitrate had been used to modulate the microbiome demonstrated that nitrate has dysbiosis-lowering properties in vitro and in vivo. Finally, 3 genera were identified that could be used for calculation of a simplified SMDI with comparable accuracy. This simplified index can be used as a basis for a point-of-care diagnostic kit. Proposed Use 1- Diagnosis of chronic periodontitis. 2- Identify patients with high susceptibility to periodontitis, e.g. patients with severe disease despite low dysbiosis. 3- Identify people at risk of developing periodontitis, e.g. patients with clinically healthy periodontium but high dysbiosis. 4- Assess response to periodontal treatment; identify sites/patients at risk of relapse. 5- Assess response to oral microbiome modulation therapies/interventions
Creator(s)
Nezar Al-Hebshi Contact J. Todd Abrams, PhD Senior Director, New Ventures and Business Development Office of the Vice President for Research Technology Commercialization and Business Development techtran@temple.edu http://www.temple.edu/research Keywords Artificial Intelligence; Diagnostics; Clinical Applications; Bioinformatics |
| Advanced biomarkers for early detection of Neural Tube Defects. C2022-018 |
About
This invention focuses on novel biomarkers for prenatal diagnosis of neural tube defects (NTDs) based on differences in the abundance and composition of central nervous system (CNS)-specific proteoglycans in amniotic fluid. NTDs occur very early in gestation (first trimester) and increase in severity during fetal development. Accurate, reliable, early diagnosis is therefore vital. Currently, NTD prenatal screening and diagnosis is based on a combination of serum alfa fetoprotein (AFP) levels and fetal ultrasound imaging. However, these methods present several disadvantages that can lead to unreliable diagnoses. More accurate and objective biomarkers for early detection of NTDs would provide not only a more reliable diagnosis, but one that would support more informed patient management decisions at much earlier timepoints. We have developed an ELISA-based diagnostic test for 2 CNS Chondroitin Sulfate Proteoglycans, that have been confirmed in a rat model. When fully developed, the test would: 1. Be more specific and accurate than the current standard for diagnosis via serum AFP plus ultrasound. 2. Be usable earlier in pregnancy than current methods. AFP is widely used but has a time window for accurate correlation with NTD and thus may not be accurate outside the time window. 3. Be less reliant on expensive imaging studies such as ultrasound that require interpretation of results by qualified technicians. Our method will be much less expensive, and performed very early in pregnancy and will benefit patients in countries with limited access to advanced prenatal care and imaging facilities. Proposed Use Early detection of neuraltube birth defects
Creator(s)
Barbara Krynska, Oleg Gordiienko, Karolina Janik, George Smith Patent Provisional PCT filed Contact J. Todd Abrams, PhD Senior Director, New Ventures and Business Development Office of the Vice President for Research Technology Commercialization and Business Development techtran@temple.edu http://www.temple.edu/research Keywords Life Sciences; Clinical Applications; Biotechnology; Diagnostics |
| Spatially Resolved Diffuse Reflectance for Transcutaneous Measurements C2022-013 |
About
Spatially Resolved Diffuse Reflectance (SRDR) is a technique for performing the TransCutaneous (TC) estimation of tissue chromophores with reduced influence from confounding parameters associated with tissue layers adjacent to the layer where the chromophores of interest reside. In contrast with prior point-of-care devices, SRDR images diffuse reflectance point-spread functions with a 2D camera module instead of the reflectance at a finite set of positions using single-point detectors. In our preliminary studies, we have performed computer simulations of the technique for estimation of both oxygenation saturation levels and bilirubin levels, indicating reduced pigmentation-dependent measurement bias and error across both scenarios when regression models are created using multiple regions of interest digitially defined across the 2D sensor field of view. In addition, we have completed human-subjects pilot studies which using this approach using a mobile-phone camera platform to quantify bilirubin in neonates. The results indicate indicate a good ability to predict bilirubin. The invention consists of an optical detection system in which a 2D sensor (camera) images the diffuse reflectance spatial decay function generated from a light source/multiple light sources incident on the surface of the tissue at certain distance offset from the camera's field of view. We have developed a multi-variate regression model constructed against the gold standard clinical measurement (i.e. Serum Bilirubin in bilirubinometry or Arterial Blood Gas Oxygenation Saturation in oximetry) using multiple spatial regions of interest in the camera field of view. In a color camera, there are 3 different (red/green/blue) detector color channels from which to extract unique regions of interest, as is the case in bilirubinometry. In the case of oximetry, these wavelength dependent channels can be the result of different light sources. An optimization algorithm is used to identify the coordinates and sizes for regions of interest which minimize model error. This device can consist of a snap on adapter to any consumer camera or mobile phone camera, or alternatively be a custom built device centered around a consumer 2D imaging module. Proposed Use -point of care bilirubinometer for screening newborns for neonatal jaundice, either as a smart phone case style adaptor/mobile phone app pair for at-home use by nurse midwives or parents, or a specific use handheld measurement device for use in low-resource settings gobally. -clinical oximeter for use in patient care , surgical, pre/post-operative settings, as well as in respiratory therapy etc. -standalone wearable consumer device measuring physiological parameters such as oximetry -electronic sensor modules which can be integrated into existing multifunction wearable technologies.
Creator(s)
Chetan Patil, Mohammed Shahriar Arefin, Alexander P. Dumont, Brandon Keith Harrison Patent Provisional Application filed Contact J. Todd Abrams, PhD Senior Director, New Ventures and Business Development Office of the Vice President for Research Technology Commercialization and Business Development techtran@temple.edu http://www.temple.edu/research Keywords Medical Devices; Clinical Applications; Instrumentation; Imaging; Diagnostics |
| ARTHROSCOPIC PROBE DEVICE, SYSTEM AND METHOD C2021-053 |
About
Arthroscopy is a routine surgical procedure used to assess joint health. With advancements in technology and improvements to traditional devices, the arthroscopic procedure volume is expected to substantially rise. We aim to develop a novel way to provide real time analysis of joint tissues by a near infrared (NIR) fiber optic probe that allows for the objective evaluation of compositional properties during routine knee arthroscopy. Our non-destructive NIR probe represents a fundamentally new and powerful approach for evaluating and guiding cartilage therapeutics. Our new NIR arthroscopic probe is designed to be externally similar to a traditional arthroscopic hook probe, but with the internal structure of a NIR fiber optic probe with fibers that span the visible and NIR spectral regions. Our innovation is a novel tool for collecting visible (Vis) and NIR spectral data that reflects composition during arthroscopic procedures. This type of device is currently not commercially available and can be competitively inserted in both the arthroscopy device market and medical fiber optics market. Our innovation is advantageous in comparison to the current joint assessment procedure of subjective palpation and interpretation using the traditional arthroscopic hook probe by providing objective quantitative information. Our design is an improved technological advance that can be easily advertised and absorbed into the surgical marketplace. Our NIR arthroscopic probe was designed with clinicians in mind to guide management of joint diseases. As noted externally, it will be similar to conventional arthroscopic hook probes in design, but with the capability of obtaining compositional information from tissues. This design criteria will facilitate its market placement and integration into routine surgical practice. NIR is a well-established and non-harmful light technology that is currently used in several FDA-approved medical devices. Proposed Use • A tool used by surgeons during routine arthroscopy to monitor (i) joint lesions (ii) joint lesions post-surgery (iii) implant integration with surrounding tissue (iv) optimal donor tissue site • Identification of optimal sites for autologous chondrocyte implantation • Objective and quantitative device for orthopedic surgeons • Real-time monitoring of biochemical composition of joint and/or implant and surrounding tissue • Real-time monitoring of degeneration and healing of joint and/or implants
Creator(s)
Nancy Pleshko, Jessica M Falcon, Shital Kandel, Jack Oswald, William Querido Maciel Patent Provisional Application Contact J. Todd Abrams, PhD Senior Director, New Ventures and Business Development Office of the Vice President for Research Technology Commercialization and Business Development techtran@temple.edu http://www.temple.edu/research Keywords Diagnostics; Instrumentation; Imaging |
| Novel endoluminal tube with medication delivery system C2021-041 |
About
The main embodiment of this medication delivery system invention is the endotracheal tube (ETT). The ETT is used to intubate the respiratory channel (i.e., the trachea) of a patient to deliver air, oxygen, and/or anesthetic gases during procedures under general anesthesia (use # 1) and for mechanical ventilation of critically ill patients in the intensive care unit (use # 2). Finally, the endotracheal tube has the added benefit of preventing gastric contents from entering the airway which can lead to aspiration pneumonia and lung damage (use # 3). The ETT is a fundamental and essential component of modern medicine with more than 313 million procedures performed annually in addition to the ETT used for mechanically ventilated patients. While ETT has multiple uses, it’s application is inherently associated with multiple adverse consequences primarily resulting from the increased circumferential pressure exerted by the inflation ETT on the tracheal mucosa enclosed within the rigid tracheal rings. The adverse consequences of the ETT include: (1) bronchospasm: constriction of the airways; (2) emergence reactions: violent and combative emergence, coughing, retching; (3) application of higher doses of anesthetic beyond the need of the procedure to counteract the stimulating effect of the ETT leading to hemodynamic instability and complications; (4) Tracheal stenosis around the inflated cuff due to prolonged endotracheal intubation in critically ill patients in intensive care unit. The aforementioned 4 adverse consequences are experienced by every medical center worldwide performing procedures and/or managing critically ill patient in the intensive care unit. The invention provides a medication delivery device configured to allow precise and controlled circumferential (or sectional) medication delivery to the interface between the endoluminal device cuff and the compressed surrounding tissue lining the lumen. The invention allows for precise, timely and accurate delivery of medication only to the surrounding compressed mucosa abutting the endoluminal tube cuff. This precise and time-controlled administration of the medication allows for using the smallest doses possible of the medication minimizing the likelihood of complication while achieving maximum clinical benefit. Injected medications include local anesthetics (solves problem 1-3), and steroids (solves problem 4). The invention is expected to minimize complication rate associated with ETT, improve clinical outcomes, and reduce healthcare cost. The invention has been experimentally verified in vitro using a calibrated setup simulating intraoperative clinical conditions encountered in everyday practice as described in peer-reviewed literature. Compared to existing and suggested solutions to the problem, the invention was proven to unequivocally solve the problem. Based on in vitro experiments and existing body of literature detailing current clinical practices, the invention is far superior to existing prior art and clinical practices. The invention can be added to all existing endoluminal devices including ETT (main embodiment) Proposed Use 1- Endotracheal tubes used during general anesthesia (main embodiment) 2- Endotracheal tubes used in the intensive care unit (main embodiment) 3- Laryngeal mask airway used during anesthesia 4- Endoluminal catheters and devices used for urological, gastroenterological, and vascular procedures.
Creator(s)
Ihab Kamel Patent Provisional Patent Application filed Contact J. Todd Abrams, PhD Senior Director, New Ventures and Business Development Office of the Vice President for Research Technology Commercialization and Business Development techtran@temple.edu http://www.temple.edu/research Keywords Medical Device; Therapeutic delivery; Clinical Applications |
| Novel use of iron chelator Deferasisox in selectively reducing the population of periodontal disease causing bacteria C2021-027 |
About
The Novartis iron chelator Deferasirox was used to test its antimicrobial activity against oral bacteria in an in vitro biofilm. Deferasirox was able to selectively reduce the population of periodontal disease causing bacteria. This is a novel application of an existing drug belonging top the class if iron chelators. The drug was able to reduce the numbers of oral bacteria that cause periodontal disease, in vitro. Bacteria were enumerated in the in vitro biofilm after day 3 and day 7 of drug application. And the dug was tested at two different concentrations. Dose-dependent antimicrobial effect was observed. The drug was selective in the eradication of mostly periodontal bacteria; and most importantly, majority of the healrthy oral bacteria were not affected. Proposed Use The drug can be incorporated into oral mouthwashes and gels for easy application through oral rinses.
Creator(s)
Sumant Puri, Nezar Al-Hebshi Contact J. Todd Abrams, PhD Senior Director, New Ventures and Business Development Office of the Vice President for Research Technology Commercialization and Business Development techtran@temple.edu http://www.temple.edu/research Keywords Therapeutics; Clinical Applications |
| A COMBINATION OF MAP ANTIBODY TESTS FOR DETECTION
OF MAP INFECTION AND THE DIAGNOSIS OF DISEASE FOR
PATIENTS WITH CROHN’S DISEASE, AUTOIMMUNE DISEASES
AND IN ASYMPTOMATIC INDIVIDUALS C2021-013 |
About
A system or method for a combination of MAP antibody tests for detection of MAP infection and the diagnosis of disease for patients with Crohn's disease, autoimmune diseases and in asymptomatic individuals, is provided. MAP is the cause of Crohn's disease (CD) first described in 1895, a zoonotic infection that affects cattle, goats, sheep and most species of wildlife throughout the world. The human population is widely exposed to the organism in the food chain since it is found in asymptomatic beef cattle and in the milk of dairy cows. Multiple international studies have shown that a proportion of MAP organisms survive the current conditions of HTST pasteurization. Two meta-analyses have concluded that the MAP organism is present in a majority of patients with CD as compared to a control population. Since the MAP theory of causation of CD gained interest following the growth of MAP from the intestinal tissues of CD patients by Rod Chiodini in 1984, multiple clinical trials of antibiotics have failed to cure CD and gastroenterologists have dismissed the MAP theory. However, this theory remains plausible and valid. What is needed is a system and/or method that satisfies one or more of these needs or provides other advantageous features. Other features and advantages will be made apparent from the present specification. The teachings disclosed extend to those embodiments that fall within the scope of the claims, regardless of whether they accomplish one or more of the aforementioned needs. The inventors have found a inventor modified modified veterinary ELISA assay detects the greatest number of subjects with MAP antibodies (70% of CD patients and 63% of non-CD controls) followed by the Bach anti Cl1 antibody (42% of CD patients and 53% of non-CD controls). These two antibodies could be used either singly or in the form of a sum of a positive result in either or both tests to screen for the presence of MAP antibodies. This part of the combination of antibodies would be useful for identifying the presence of the organism in the host, i.e., infection, rather than identifying the presence of disease. In the current MAP/CD study, the two antibodies which are best at discriminating the presence of disease include the Zhang Hsp65 antibody and the Bach pKnG antibody. Amongst the several serology tests, the highest correlation to the presence of CD 5 occurred with the Zhang Hsp antibody. At a cutoff value > 0.74, this method had the best ability to discriminate between CD patients and non-CD controls (OR (95% CI) of having CD comparing Zhang Hsp > 0.74 vs. Zhang Hsp ≤ 0.74: 2.40 (1.25, 4.61)) with p-value 0.009 and fisher exact p value 0.020. The Bach pknG anitbody also had a significant correlation to the CD/UC patients as compared to the non-CD/UC controls.These antibodies could be used individually to identify those patients with CD or Sjogren’s Syndrome (SJS). In as yet unpublished work, the Zhang Hsp65 antibody is positive in similar proportions among patients with CD (67.9% or 74 of 109 patients) and SJS (85.7% or 24 of 28 patients). In a population of 288 healthy blood donors, only 8 donors or 2.8% had Hsp65 IgG antibodies. Based on previously published MAP prevalence studies in multiple sclerosis (MS) and type I diabetes mellitus (T1DM), there is a high probability that patients with these diseases also have a high rate of Hsp65 IgG. The discriminatory ability of these antibodies to identify the presence of a MAP caused disease would be increased when both antibodies are positive. In other words, any subject with positive results in both the Hsp65 and the Bach pKnG has a very high probability of suffering from a MAP caused illness. Proposed Use The final product includes a panel of serologic antibody tests for the detection of infection by Mycobacterium avium ssp. paratuberculosis (MAP) organisms. The kit will include all of the items required for the detection of MAP infection in a routine hospital microbiology laboratory. Adoption of these antibody methods will lead to widespread testing for this bacterium in the general population. Most diseases considered of unknown or “autoimmune” etiology including Crohn’s disease (CD), complex regional pain syndrome (CRPS) and Alzheimer’s disease (AD) will be investigated for a MAP causation and MAP will be implicated in some of these diseases. Published studies from Europe indicate an increased prevalence of MAP infection in patients with type I diabetes mellitus (T1DM) and multiple sclerosis (MS) thus raising the possibility of an etiologic role of MAP in these conditions. This phenomenon will lead to widespread testing of the human population and to improved public health measures that limit the introduction of MAP to the food supply.
Creator(s)
John Todd Kuenstner, Raghava Potula Patent 62/942,480; PCT/US20/62642 Contact J. Todd Abrams, PhD Senior Director, New Ventures and Business Development Office of the Vice President for Research Technology Commercialization and Business Development techtran@temple.edu http://www.temple.edu/research |
| Ancestry Adjusted Calcitriol-24,25-dihydroxyvitamin D3-calcifediol proportion ratio (C24CPR) for Secondary and Tertiary Prevention C2021-007 |
About
The US Preventive Services Task Force and the National Academy of Medicine (formerly the Institute of Medicine) have called for improved circulating biomarkers of vitamin D status to be used in screening healthy adults for low vitamin D status. In light of this recognized need, we propose the calcitriol-24,25-dihydroxyvitamin D3-calcifediol proportion ratio (C24CPR). Higher C24CPR values theoretically describe a greater production of 1,25(OH)2D3 relative to 24,25(OH)2D3, adjusted for the upstream reserve of 25(OH)D3. Adjustment using genetic ancestry informative markers (AIMs) will further improve the use of C24CPR in precision medicine settings. CYP24A1 is the major vitamin D catabolic enzyme for which at least three major metabolites compete. These include 25(OH)D3, 24,25(OH)2D3, and the active form of vitamin D (1,25(OH)2D3). The C24CPR biomarker is developed under the concept of CYP24A1 enzyme metabolite competition. All three metabolites which make up the balance of C24CPR compete for catabolism by this mitochondrial enzyme. The "active" form of vitamin D, known as calcitriol (aka 1,25(OH)2D3) is the only vitamin D metabolite known to influence downstream gene function via the vitamin D receptor (VDR) at picomolar concentrations. Higher C24CPR values theoretically describe a greater production of 1,25(OH)2D3 relative to 24,25(OH)2D3, adjusted for the upstream reserve of 25(OH)D3. C24CPR calculation requires plasma measurement of all three metabolites using high performance liquid chromatography and tandem mass spectrometry (HPLC-MS/MS). Details regarding the assay and development of ancestry informative markers are provided in Wilson (2018) and Wilson (2011); details regarding the calculation are provided in Wilson (2020); and molecular rationale for differential CYP24A1 expression according to genetic ancestry (Wilson, 2008). Ancestry-adjustment of C24CPR requires genotyping for Ancestry Informative Markers (AIMs) (Wilson, 2018; Wilson, 2020). Globally, genetic variability (i.e., frequency of novel single nucleotide polymorphic variants) among African populations is greatest and consistent with the “out of Africa” hypothesis (McEvoy, 2011). This is a major reason why we have developed a West African genetic-ancestry-adjusted measure of C24CPR. We propose that our novel model will permit a more accurate analysis and management of vitamin D and its metabolites in an individual. Proposed Use Potential uses of C24CPR: 1) The system can be used for screening for CYP24A1 Inhibitor Therapy. 2) Monitoring for Risk of Bone Depletion in Glucocorticoid Treatment. 3) Screening for Idiopathic Infantile Hypercalcemia (IIH) and Reduced Function CYP24A1 Mutations. 4) Screening Among Healthy Individuals. Calcitriol (1,25(OH)2D3) and 25(OH)2D3 alone has been associated with a healthy lifestyle (Kohler, 2017). a. We have shown that, compared with a crude ratio, improved distributional characteristics of C24CPR using our method. b. Our model assess C24CPR in healthy individuals to identify decrements in renal function which may be a consequence of cumulative environmental insults through heavy metals and persistent per- and poly-fluorinated compounds (PFAS) in ambient air and drinking water. c. C24CPR appears to be a distinct marker of vitamin D status in healthy young adults that is capturing something distinct from the “active form” of vitamin D, calcitriol (1,25(OH)2D3). i. Our model accounts for the observed gene variants associated with the C24CPR biomarker that are not the same as the pattern of gene variants associated with calcitriol (1,25(OH)2D3). ii. Sunlight and tanning bed induced a significant dose-response decrease in C24CPR. This unexpected result may have important health consequences. iii. Oral contraceptive use is well-known to increase plasma/serum calcitriol (1,25(OH)2D3) and 25(OH)D concentrations. We observed a significant decrease in C24CPR with among oral contraceptive users that appeared to be dose-dependent. iv. Compared with calcitriol (1,25 (OH)2D3), a greater proportion of the C24CPR biomarker can be explained by known genetic and environmental factors (49.5 versus 37.4 percent, respectively). d. Factors associated with higher bone mineral density (i.e., male sex, higher BMI, and African American ancestry) are associated with higher C24CPR values in young healthy adults (ages 18-35). These associations are distinct from those with calcitriol.
Creator(s)
Robin T Wilson Patent Provisional Patent Application has been filed. Contact J. Todd Abrams, PhD Senior Director, New Ventures and Business Development Office of the Vice President for Research Technology Commercialization and Business Development techtran@temple.edu http://www.temple.edu/research Keywords Diagnostics; Therapeutics; Research Tools |
Showing 1 to 10 of 62 entries